Skip to main content

Comprehensive Hepatitis Testing

Viral hepatitis remains one of the most underdiagnosed and undertreated infectious diseases in the United States. Millions of people live with chronic Hepatitis B or C without knowing their status, placing them at risk for cirrhosis, liver failure and hepatocellular carcinoma.¹⁻⁹
A male doctor of Middle Eastern decent holds out a tablet as he takes notes during a medical appointment with a senior patient. He is wearing blue scrubs and has a white lab coat overtop, and the patient is dressed casually and has his back to the camera.


Key unmet needs in clinical practice

Why comprehensive hepatitis testing matters

Significant gaps remain in hepatitis diagnosis and care. Even when screening occurs, many patients fall out of care after positive antibody results due to the absence of reflex RNA testing pathways¹³. Hepatitis D testing also remains underutilized, despite its association with severe disease and the emergence of new therapies¹⁰⁻¹².

At the same time, primary care providers frequently report low confidence interpreting complex hepatitis serologies, which can further complicate patient management¹⁴. Fragmented testing approaches often lead to delayed treatment initiation and lost follow-up¹³, and disparities in diagnosis and care continue to affect immigrant, rural, and underserved populations¹⁵. Many health systems also lack automated reflex testing pathways that could simplify diagnosis and improve linkage to care¹³.

Labcorp's hepatitis portfolio

Labcorp’s comprehensive hepatitis testing portfolio supports clinicians at every step — from screening and diagnosis to treatment selection and disease monitoring — across Hepatitis A, B, C and D. Our portfolio aligns with CDC, USPSTF and professional society guidelines to help providers close diagnostic gaps and improve patient outcomes.3-12

Hepatitis A (HAV)

Labcorp offers HAV antibody testing to support acute infection diagnosis and immunity assessment.

Young man holding his arm as he is leaning up against a fence

Hepatitis B (HBV)

Early and comprehensive HBV testing is critical to identify infected individuals, monitor disease progression, and enable timely intervention to reduce long-term morbidity and mortality.

Provider sitting on a desk while on the phone

Hepatitis C (HCV)

Hepatitis C Virus screening options and understand tests for HCV infection to make confident decisions on diagnosis and managing positive results.

Group of five diverse friends stading in a link talking and laughing with each other

Hepatitis D (HDV)

Get detailed info on HDV antibody and RNA tests, who needs screening, and how test outcomes guide management.

Male doctor counseling mature patient in waiting room. Medical professional is listening to ill man while holding digital tablet in hospital. They are sitting on seat.

Featured tests

Confident answers across the full hepatitis patient journey

Recent guideline updates now call for universal and expanded screening for Hepatitis B and C, creating an urgent need for accurate, accessible and comprehensive diagnostic solutions. 6-9

144473

Hepatitis B Virus triple panel

Comprehensive HBV screen to determine HBV status (acute, chronic, immune, or susceptible); aligns with current CDC screening guidelines⁶ for all populations, including pregnant individuals. Includes HBsAg, anti-HBs, anti-HBc; reflexes to IgM anti-HBc when indicated

144103

Hepatitis B virus (HBV) triple panel with reflex to Hepatitis D virus (HDV) Antibody

A comprehensive HBV screening panel performs the full HBV triple panel and automatically adds HDV antibody testing when HBsAg is positive. This reflex pathway helps identify patients at risk for Hepatitis D coinfection, which occurs in an estimated 3–5% of HBsAg positive individuals¹⁰ and is associated with more rapid progression to cirrhosis and advanced liver disease¹¹.

144050

Hepatitis C virus antibody with reflex

This initial screening test for HCV infection automatically proceeds to HCV RNA quantitative PCR testing if the HCV antibody result is positive, allowing for confirmation of active infection or evidence of a prior resolved infection. The reflex workflow streamlines diagnosis by removing the need for additional provider orders and enables timely identification of patients who require further clinical evaluation and treatment.

144226

Hepatitis A virus antibody, total with reflex to IgM

Detects total HAV antibodies (IgG + IgM) with automatic reflex to IgM when positive to help distinguish acute infection from past infection or vaccination.

Labcorp is closing the gaps in Hepatitis screening, diagnosis and monitoring with a comprehensive testing portfolio

Despite evolving clinical guidelines and growing public health awareness, gaps remain in hepatitis screening, diagnosis and long-term disease management. Labcorp’s comprehensive hepatitis portfolio is designed to help providers address these challenges and support patients across the full continuum of care.

Icon of a scientist with a beaker

Comprehensive viral Hepatitis portfolio (A through D)

Labcorp offers one of the most comprehensive hepatitis testing portfolios available, supporting detection and management across Hepatitis A, B, C and D to help providers deliver more complete liver disease evaluation.

Icond of a gear with a circle of arrows around it

Reflex testing algorithms

Automated reflex pathways streamline testing by moving from screening to confirmatory and follow-up tests when clinically appropriate. This reduces missed diagnoses, minimizes additional specimen collections and helps accelerate time to diagnosis.

Icon of a check mark within a badge

Guideline-aligned panels

Comprehensive hepatitis panels are designed to align with recommendations from organizations such as the Centers for Disease Control and Prevention, American Association for the Study of Liver Diseases and U.S. Preventive Services Task Force. These panels simplify ordering and help ensure patients receive appropriate screening and diagnostic evaluation.

Icon of a delivery truck

Nationwide access and logistics

Labcorp’s national infrastructure supports convenient specimen collection through a broad network of patient service centers and integrated logistics capabilities, helping providers deliver hepatitis testing access to patients across diverse care settings.

Icon of a cliboard with a chart on it

Decision support and interpretive reporting

Structured reporting and interpretive comments help clinicians navigate complex hepatitis serology patterns, improving result clarity and supporting appropriate clinical follow-up and treatment decisions.

Icon of a screen with a monitor line on it

End-to-end disease monitoring

From initial screening and diagnosis to treatment monitoring and long-term management, Labcorp offers testing solutions that support the full hepatitis care continuum.

Icon of a test tube with a magnifying glass over it

Reflex pathways supporting expanded detection

Advanced reflex strategies, such as reflexing from Hepatitis B screening results to additional testing when clinically indicated, can help identify patients who may require further evaluation for coinfections or disease staging.

Icon of three heads with a plus sign

Scalable testing solutions for population screening

Labcorp supports large-scale screening initiatives aligned with public health recommendations, helping health systems, primary care providers and community programs expand hepatitis detection and linkage to care.

Connect with our team to learn more

References

  1. CDC – HAV Seroprevalence (NHANES) - https://www.cdc.gov/hepatitis/hav/statistics/index.htm
  2. CDC – HAV Outbreaks (2016–2024) - https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm
  3. CDC – HAV Clinical Overview - https://www.cdc.gov/hepatitis/hav/havfaq.htm
  4. CDC – Viral Hepatitis Surveillance (2022) - https://www.cdc.gov/hepatitis/statistics/2022surveillance/index.htm
  5. CDC – Viral Hepatitis Surveillance (2019–2020) https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm
  6. CDC – Hepatitis B Screening Guidelines (2023) - https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm
  7. AASLD – Hepatitis B Treatment Guidance - https://www.aasld.org/practice-guidelines/hepatitis-b
  8. CDC – Hepatitis C FAQ - https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm
    8a. USPSTF – Hepatitis C Screening Recommendation - https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening
  9. CDC – HCV Mortality & Burden - https://www.cdc.gov/hepatitis/hcv/index.htm
    9c. CDC – Reflex RNA Testing Guidance - https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm
  10. Patel EU et al. – U.S. HDV Prevalence (Journal of Infectious Diseases) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439036/
  11. AASLD – Hepatitis D Diagnosis & Management - https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hepatitis-d-diagnosis-and-management
  12. EASL – Clinical Practice Guidelines on HDV - https://easl.eu/publication/the-management-of-hepatitis-b-virus-infection-2017/
  13. ehia BR et al. – Gaps in HCV Care Continuum - https://pubmed.ncbi.nlm.nih.gov/26675758/
  14. Wong RJ et al. – Provider Knowledge Gaps in Viral Hepatitis - https://pubmed.ncbi.nlm.nih.gov/31420938/